Therapeutic potential of mesenchymal stromal/stem cells in critical-care patients with systemic inflammatory response syndrome.

ABSTRACT:

Background

Despite notable advances in the support and treatment of patients admitted to the intensive care unit (ICU), the management of those who develop a systemic inflammatory response syndrome (SIRS) still constitutes an unmet medical need.

Main body

Both the initial injury (trauma, pancreatitis, infections) and the derived uncontrolled response promote a hyperinflammatory status that leads to systemic hypotension, tissue hypoperfusion and multiple organ failure. Mesenchymal stromal/stem cells (MSCs) are emerging as a potential therapy for severe ICU patients due to their potent immunomodulatory, anti-inflammatory, regenerative and systemic homeostasis-regulating properties. MSCs have demonstrated clinical benefits in several inflammatory-based diseases, but their role

SUBMITTER: Marti-Chillon GJ 

PROVIDER: S-EPMC9806020 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature